Patent ID: 8580513

Claim:
A method for determining response to neoadjuvant therapy in pancreatic ductal adenocarcinoma (PDAC) comprising (a) obtaining a biological sample from a patient with PDAC; (b) determining the level of microRNA-10b in the biological sample with a microRNA-10b specific probe having the sequence 5′-CA+CAA+ATT+CGG+TT+CTA+CAG+GGTA-3′ (SEQ ID NO:3), wherein +N denotes a locked nucleic acid modified nucleotide; (c) comparing the level of microRNA-10b in the biological sample to control samples expressing relatively low, medium or high levels of microRNA-10b; and (d) diagnosing response of the patient to neoadjuvant therapy, wherein a level of microRNA-10b expression in the biological sample comparable to the control sample expressing a relatively low level of microRNA-10b indicates that the patient is likely to respond to neoadjuvant therapy.